Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study” and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid

Schwager, Zachary; Mikailov, Anar; Lipworth, Adam D.

doi:10.1016/j.jaad.2019.01.086

Cited by 4 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as these studies were conducted in 2018, new-generation diabetic medications were being taken by very few patients. In more recent studies, a possible association has been reported with previous exposure to a sodium glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist, suggesting the need for further large-scale epidemiological studies in the future [82,83].…”

Section: Risk Of Bp Development In Patients With Diabetes Mellitus In...mentioning

confidence: 99%

From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid

de Nicolas-Ruanes,

Ballester-Martinez,

Garcia-Mouronte

et al. 2023

IJMS

View full text Add to dashboard Cite

Bullous pemphigoid (BP), the most common autoimmune blistering disease, is characterized by the presence of autoantibodies targeting BP180 and BP230 in the basement membrane zone. This leads to the activation of complement-dependent and independent pathways, resulting in proteolytic cleavage at the dermoepidermal junction and an eosinophilic inflammatory response. While numerous drugs have been associated with BP in the literature, causality and pathogenic mechanisms remain elusive in most cases. Dipeptidyl peptidase 4 inhibitors (DPP4i), in particular, are the most frequently reported drugs related to BP and, therefore, have been extensively investigated. They can potentially trigger BP through the impaired proteolytic degradation of BP180, combined with immune dysregulation. DPP4i-associated BP can be categorized into true drug-induced BP and drug-triggered BP, with the latter resembling classic BP. Antineoplastic immunotherapy is increasingly associated with BP, with both B and T cells involved. Other drugs, including biologics, diuretics and cardiovascular and neuropsychiatric agents, present weaker evidence and poorly understood pathogenic mechanisms. Further research is needed due to the growing incidence of BP and the increasing identification of new potential triggers.

show abstract

Section: Risk Of Bp Development In Patients With Diabetes Mellitus In...mentioning

confidence: 99%

From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid

de Nicolas-Ruanes,

Ballester-Martinez,

Garcia-Mouronte

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…To the Editor: We thank Schwager et al 1 for their interest in our recent publications. 2,3 They comment that the title of our article 3 may mislead the reader into prematurely ruling out oral diabetes medications other than gliptins as a possible aggravating factor for bullous pemphigoid (BP).…”

mentioning

confidence: 99%

Reply to: “Comment on ‘Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study’ and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid”

Varpuluoma

Tasanen

Huilaja

2019

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Dulaglutide

2019

Reactions Weekly

View full text Add to dashboard Cite

Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study” and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid

Cited by 4 publications

References 2 publications

From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid

From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid

Reply to: “Comment on ‘Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study’ and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid”

Dulaglutide

Contact Info

Product

Resources

About